

Accelerate biomarker discovery and target identification with Ovation IBD Omics Data



Ovation IBD Omics Data Details

■ Sequenced cohort includes 212 patients:

- **WGS** (30x Depth, VCF Files)
- **Total RNA-Seq** on diseased and normal tissue
- **Clinical data** for all patients
- Scheduled to sequence 3,000 additional tissue samples in 2024

■ Available IBD tissue samples inclusive of various conditions:

- Crohn's Disease: **1,719 patients**
- Ulcerative Colitis: **2,783 patients**
- Unspecified IBD: **4,297 patients**
- Non-IBD Controls: **13,000+**

■ Omics data is **tokenized and linked to longitudinal clinical data** across the patient journey, including full redacted pathology reports, disease severity (from pathology), comorbidity diagnoses, therapeutic exposures, medical procedures, and surgical history

Top Medications

Mesalamine
Prednisone
Budesonide
Hydrocortisone
Methylprednisolone
Infliximab
Adalimumab
Metronidazole
Vedolizumab

Top Comorbidities

Diarrhea
Abdominal Pain
Hyperlipidemia
Gastritis
Hypertension
Anemia
Vitamin D Deficiency

Ovation provides access to **Diverse and Representative Populations with IBD:**


32% Hispanic
~1,160 Patients from Underrepresented Groups

Understand the longitudinal patient journey

98% of patients have >180 days of post-diagnosis data. 78% of patients have >180 days of pre-diagnosis clinical data.


Average Per Patient

Diagnoses: **83**
Procedures: **79**
Medications: **27**




Guide the sequencing of targeted IBD cohorts of interest

In addition to our existing cohort of sequenced patients, Ovation generates novel datasets by sequencing material from our biobank of thousands of IBD tissue samples indexed with clinical annotation. Life sciences partners have the opportunity to guide the cohort selection process to align with their research objectives.



Detailed patient profiles with linked clinical data

Ovation links our omics data to a variety of clinical data sources including claims, EHR, and pathology using universal token technology. Detailed, longitudinal medical history ensures researchers understand where each patient stands in their clinical journey.



Diverse patient cohorts inclusive of underrepresented populations

Ovation's IBD Omics Data includes cohorts representative of the U.S. population with geographic, ethnic, and racial diversity. This helps fill a significant gap in the current landscape of IBD genomic data, which is predominantly derived from individuals of European ancestry.



Maximize the likelihood of discovery with multiomics data

Complex diseases like IBD require a systems biology approach. Integrating patient genomic, transcriptomic, and clinical data simultaneously has enabled researchers to identify patterns previously impossible to discern.